Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
93 hedge funds and large institutions have $42.2M invested in Carisma Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 29 reducing their positions, and 27 closing their positions.
0.07% less ownership
Funds ownership: 1.29% → 1.22% (-0.07%)
5% less capital invested
Capital invested by funds: $44.5M → $42.2M (-$2.3M)
10% less funds holding
Funds holding: 103 → 93 (-10)
10% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 29
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
58% less call options, than puts
Call options by funds: $1.28M | Put options by funds: $3.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.57M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.18M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.9M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$678K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$449K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$2.29M |
| 2 |
Two Sigma Advisers
New York
|
-$1.93M |
| 3 |
Renaissance Technologies
New York
|
-$1.25M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$996K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$750K |
CARM Hedge Fund Activity: Q4 2021 in Review
93 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2021, worth a combined $42.2M — down 5.2% from $44.5M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CARM and 18 opened new positions — a net loss of 9 holders — while 29 trimmed existing stakes and 26 added.
The largest buyer was BlackRock, adding an estimated $2.57M. The largest seller was Two Sigma Investments, cutting an estimated $2.29M.
- 93 institutional investors held Carisma Therapeutics (CARM) as of Q4 2021, down from 103 in Q3 2021.
- Funds reported $42.2M of Carisma Therapeutics stock for Q4 2021, down 5.2% quarter-over-quarter.
- 18 funds opened new Carisma Therapeutics positions in Q4 2021 and 27 closed out, a net change of -9 holders.
- The largest Carisma Therapeutics buyer in Q4 2021 was BlackRock, an estimated $2.57M added.
- The largest Carisma Therapeutics seller in Q4 2021 was Two Sigma Investments, an estimated $2.29M sold.
Based on aggregated 13F filings for Q4 2021.